| Baloxavir marboxil for uncomplicated influenza in adults and adolescents FG Hayden, N Sugaya, N Hirotsu, N Lee, MD de Jong, AC Hurt, T Ishida, ... New England Journal of Medicine 379 (10), 913-923, 2018 | 889 | 2018 |
| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 580 | 2008 |
| Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a … M Bassetti, R Echols, Y Matsunaga, M Ariyasu, Y Doi, R Ferrer, TP Lodise, ... The Lancet Infectious Diseases 21 (2), 226-240, 2021 | 579 | 2021 |
| Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non … S Portsmouth, D van Veenhuyzen, R Echols, M Machida, JCA Ferreira, ... The Lancet Infectious Diseases 18 (12), 1319-1328, 2018 | 379 | 2018 |
| Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions P Mwaba, J Mwansa, C Chintu, J Pobee, M Scarborough, S Portsmouth, ... Postgraduate medical journal 77 (914), 769-773, 2001 | 242 | 2001 |
| An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals M Nelson, S Portsmouth, J Stebbing, M Atkins, A Barr, G Matthews, ... Aids 17 (1), F7-F10, 2003 | 234 | 2003 |
| Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial MG Ison, S Portsmouth, Y Yoshida, T Shishido, M Mitchener, K Tsuchiya, ... The Lancet Infectious Diseases 20 (10), 1204-1214, 2020 | 199 | 2020 |
| A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma S Portsmouth, J Stebbing, J Gill, S Mandalia, M Bower, M Nelson, ... Aids 17 (11), F17-F22, 2003 | 196 | 2003 |
| Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza T Uehara, FG Hayden, K Kawaguchi, S Omoto, AC Hurt, MD De Jong, ... The Journal of infectious diseases 221 (3), 346-355, 2020 | 183 | 2020 |
| Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial SMART Study Group* Annals of internal medicine 149 (5), 289-299, 2008 | 165 | 2008 |
| Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc LC Swenson, T Mo, WWY Dong, X Zhong, CK Woods, A Thielen, ... Clinical infectious diseases 53 (7), 732-742, 2011 | 115 | 2011 |
| Better maintained adherence on switching from twice‐daily to once‐daily therapy for HIV: a 24‐week randomized trial of treatment simplification using stavudine prolonged … SD Portsmouth, J Osorio, K McCormick, BG Gazzard, GJ Moyle HIV medicine 6 (3), 185-190, 2005 | 92 | 2005 |
| Paclitaxel for anthracycline-resistant AIDS-related Kaposi’s sarcoma: clinical and angiogenic correlations J Stebbing, A Wildfire, S Portsmouth, T Powles, C Thirlwell, P Hewitt, ... Annals of Oncology 14 (11), 1660-1666, 2003 | 79 | 2003 |
| A questionnaire survey of stress and bullying in doctors undertaking research J Stebbing, S Mandalia, S Portsmouth, P Leonard, J Crane, M Bower, ... Postgraduate Medical Journal 80 (940), 93-96, 2004 | 71 | 2004 |
| The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1–infected “true” long-term nonprogressors J Stebbing, B Gazzard, L Kim, S Portsmouth, A Wildfire, I Teo, M Nelson, ... Blood, The Journal of the American Society of Hematology 101 (10), 4000-4004, 2003 | 64 | 2003 |
| Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study DAJ Moore, T Benepal, S Portsmouth, J Gill, BG Gazzard Clinical infectious diseases 32 (3), 469-475, 2001 | 63 | 2001 |
| LB16. Phase 3 trial of baloxavir marboxil in high-risk influenza patients (CAPSTONE-2 Study) MG Ison, S Portsmouth, Y Yoshida, T Shishido, F Hayden, T Uehara Open Forum Infectious Diseases 5 (Suppl 1), S764, 2018 | 61 | 2018 |
| Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor J Stebbing, B Gazzard, S Portsmouth, F Gotch, L Kim, M Bower, ... Blood 102 (5), 1806-1814, 2003 | 57 | 2003 |
| Cefiderocol for the treatment of infections due to metallo-B-lactamase–producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies JF Timsit, M Paul, RK Shields, R Echols, T Baba, Y Yamano, ... Clinical Infectious Diseases 75 (6), 1081-1084, 2022 | 55 | 2022 |
| Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial RA McGovern, A Thielen, S Portsmouth, T Mo, W Dong, CK Woods, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 61 (3), 279-286, 2012 | 55 | 2012 |
Justin StebbingImperial College在 imperial.ac.uk 的电子邮件经过验证
